Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK112 + AK117 + carboplatin + 5-fluorouracil
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of **AK112 (Ivonescimab)**, a bispecific monoclonal antibody targeting PD-1 and VEGF-A; **AK117 (Ligufalimab)**, an anti-CD47 monoclonal antibody; plus the chemotherapeutic agents **carboplatin** (a platinum-based compound that causes DNA crosslinks) and **5-fluorouracil** (an antimetabolite that inhibits thymidylate synthase). AK112 is designed to simultaneously stimulate anti-tumor immunity and inhibit angiogenesis. AK117 blocks CD47 to enhance macrophage-mediated phagocytosis of tumor cells. Combining these immunotherapies with platinum-based and antimetabolite chemotherapy provides a multi-modal antitumor effect targeting the tumor microenvironment, immune evasion, and DNA replication. This regimen is in development for advanced malignant tumors, including gastrointestinal cancers, head and neck squamous cell carcinoma, and colorectal cancer[1][2][3][4][5].
- Brand names
- LigufalimabIvonescimab
- Other names
- AK112 + AK117 + carboplatin + 5-fluorouracil
02
Targets
CD47 (Cluster of Differentiation 47)DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on AK112 + AK117 + carboplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK112 + AK117 + carboplatin + 5-fluorouracil.